Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11062437 | 0.86 | ALDH1A1 (0.35) | L3MBTL1CYP1A2CYP3A4GLAMAPT | |
| SCHEMBL11058186 | 0.78 | ALDH1A1 (0.33) | L3MBTL1CYP1A2CYP3A4GLAMAPT | |
| SCHEMBL11058659 | 0.77 | L3MBTL1 (0.41) | L3MBTL1CYP1A2CYP3A4GLAMAPT | |
| SCHEMBL11057358 | 0.75 | MAP3K7 (0.36) | L3MBTL1CYP1A2CYP3A4MAPT | |
| SCHEMBL11060673 | 0.74 | MAPK1 (0.35) | — | |
| SCHEMBL11058666 | 0.73 | ATR (0.37) | L3MBTL1CYP1A2CYP3A4GLAMAPT | |
| SCHEMBL11058623 | 0.70 | ATR (0.40) | L3MBTL1CYP1A2CYP3A4GLAMAPT | |
| SCHEMBL21254510 | 0.69 | KMT2A (0.34) | L3MBTL1MAP4K1CYP17A1 | |
| SCHEMBL7345038 | 0.69 | HSPA5 (0.36) | CYP1A2CYP3A4MAPT | |
| SCHEMBL6114006 | 0.67 | GSK3B (0.47) | L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4434167-A | Pyrimidyl thioureas useful for the treatment of hypertension and hyperlipidemia | BEIERSDORF AKTIENGESELLSCHAFT (DE) | 1984-02-28 | — | — | US | disclosed |